Results 31 to 40 of about 153,854 (301)

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Paraquat disrupts the blood–brain barrier by increasing IL-6 expression and oxidative stress through the activation of PI3K/AKT signaling pathway

Open Medicine
Paraquat (PQ) is a frequently used herbicide with neurotoxic effects after acute or chronic exposure. Although in vitro evidence supports the PQ toxicity to dopamine cells, its in vivo effects (especially the chronic exposure) remain ambiguous.
Liu Tao, Zheng Fenshuang, Liu Lin, Zhou Hua, Shen Tao, Li Yanping, Zhang Wei   +6 more
doaj   +1 more source

review on the role of nanoparticles for targeted brain drug delivery

EXCLI Journal : Experimental and Clinical Sciences
Unfortunately, nowadays, brain disorders, which include both neurological and mental disorders, are the main cause of years spent living with a disability worldwide. There are serious diseases with a high prevalence and a high mortality rate.
Payam Nawzad Mohammed, Narmin Hamaamin Hussen, Aso Hameed Hasan, Hozan Jaza Hama Salh, Joazaizulfazli Jamalis, Sumeer Ahmed, Ajmal R. Bhat, Mohammad Amjad Kamal   +7 more
doaj   +1 more source

Choroid Plexus Enlargement and USPIO‐Based Inflammatory Feature in Cerebral Small Vessel Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choroid plexus (CP) is a key component of the blood–cerebrospinal fluid barrier (BCSFB), but its mechanism of action in cerebral small vessel disease (CSVD) remains unclear. This study investigated CP volume (CPV) alterations and their association with conventional imaging markers in CSVD and explored the underlying role of ...
Yongqiang Qu, Xiaoning Ren, Cuihua Fan, Chun Li, Lijie Zhang, Zaiqiang Zhang, Shaowu Li, Zhongmeng Lai, Bin Cai, Ying Fu, Yi Lin, Zhibao Zhu   +11 more
wiley   +1 more source

Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer

Cancer Biology & Medicine
A significant number of anticancer drugs fail to treat primary and metastatic brain tumors primarily because of the complex blood-brain barrier (BBB) and overexpression of ATP-binding cassette (ABC) transporters, which decrease drug penetration into the ...
Haneen Amawi, Alaa M. Hammad, F. Scott Hall, Noor Hussein, Aseel O. Rataan, Abeer Mrayyan, Taqwa Al-kofahi, Ali Hmedat, Charles R. Ashby, Amit K. Tiwari   +9 more
doaj   +1 more source

Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier

Advanced Science, 2021
The blood–brain barrier (BBB) is a highly specialized neurovascular unit, initially described as an intact barrier to prevent toxins, pathogens, and potentially harmful substances from entering the brain.
Jia Li, Meng Zheng, Olga Shimoni, William A. Banks, Ashley I. Bush, Jennifer R. Gamble, Bingyang Shi   +6 more
doaj   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Design, optimization and evaluation of an ion-triggered in situ nasal gel of selegiline for antidepressant therapy

Journal of Applied Pharmaceutical Research
Background: Oral delivery of selegiline is limited by extensive first-pass metabolism, low and variable bioavailability, and restricted brain access due to the blood–brain barrier.
Antesh Kumar Jha, Shiv Kumar Srivastava, Mahesh Prasad, Shashi Shankar, Abhishek Kumar Singh   +4 more
doaj   +1 more source

Reduction in pericyte coverage leads to blood–brain barrier dysfunction via endothelial transcytosis following chronic cerebral hypoperfusion

Fluids and Barriers of the CNS, 2021
Background Chronic cerebral hypoperfusion (CCH) is the leading cause of cerebral small vessel disease (CSVD). CCH is strongly associated with blood–brain barrier (BBB) dysfunction and white matter lesions (WMLs) in CSVD.
Zhengyu Sun, Chenhao Gao, Dandan Gao, Ruihua Sun, Wei Li, Fengyu Wang, Yanliang Wang, Huixia Cao, Guoyu Zhou, Jiewen Zhang, Junkui Shang   +10 more
doaj   +1 more source

Peripheral Neutrophil Activation and Extracellular Trap Formation in Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
Markers of neutrophil activation are increased in plasma during ALS, and markers of NET formation associate with ALS survival. ABSTRACT Objectives Peripheral neutrophil levels in amyotrophic lateral sclerosis (ALS) inversely correlate with survival, suggesting a role for neutrophils in disease progression.
Lillia A. Baird, Haley McQuown, Jihyun Park, Samuel J. Teener, Ian F. Webber‐Davis, Andrew D. Carter, Dae‐Gyu Jang, Eva L. Feldman, Stephen A. Goutman, Benjamin J. Murdock   +9 more
wiley   +1 more source